Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to...

Celý popis

Podrobná bibliografia

Vydané v:	The lancet oncology Ročník 18; číslo 7; s. 863 - 873
Hlavní autori:	Davies, Michael A, Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Flaherty, Keith T, Arance, Ana, Chiarion-Sileni, Vanna, Thomas, Luc, Lesimple, Thierry, Mortier, Laurent, Moschos, Stergios J, Hogg, David, Márquez-Rodas, Iván, Del Vecchio, Michele, Lebbé, Céleste, Meyer, Nicolas, Zhang, Ying, Huang, Yingjie, Mookerjee, Bijoyesh, Long, Georgina V
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Elsevier Ltd 01.07.2017 Elsevier Limited
Predmet:	Brain cancer Fever Headache Hematology, Oncology and Palliative Medicine Inhibitor drugs Kinases Melanoma Metastases Metastasis Platinum Studies Targeted cancer therapy Toxicity
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!